var data={"title":"Doxapram: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Doxapram: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6071?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=doxapram-drug-information\" class=\"drug drug_general\">see &quot;Doxapram: Drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F162830\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Dopram</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1058200\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Central Nervous System Stimulant</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Respiratory Stimulant</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11442336\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Apnea of prematurity</b>: Limited data available:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Loading dose: IV: 2.5 to 3 mg/kg (Bhatt-Mehta 2003; Peliowski 1990; Tay-Uyboco 1991)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Maintenance dose: Continuous IV infusion: Initial: 0.5 to 1.5 mg/kg/<b>hour</b>; increase in increments of 0.5 mg/kg/<b>hour</b> as needed to control apnea up to a maximum rate of 2.5 mg/kg/<b>hour</b>; once stable titrate to the lowest rate at which apnea is controlled; assess benzyl alcohol exposure particularly with higher doses or continued use (Barrington 1987; Bhatt-Mehta 2003; Peliowski 1990, Sreenan 2001; Tay-Uyboco 1991). <b>Note:</b> Typically considered third-line agent.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F47068082\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=doxapram-drug-information\" class=\"drug drug_general\">see &quot;Doxapram: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Although manufacturer's dosing recommendations are presented for these FDA-approved indications, use of doxapram has largely been replaced by alternate preferred agents.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Drug-induced CNS depression:</b> Children &ge;12 years and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV<i>:</i> Initial: Priming dose of 1 to 2 mg/kg; repeat after 5 minutes; may repeat at 1 to 2 hour intervals (until sustained consciousness); if relapse occurs may resume repeat doses at 1 to 2 hour intervals until sustained consciousness or maximum dose reached; maximum daily dose: 3,000 mg/<b>day</b>. May repeat in 24 hours if necessary; repeat doses should only be given to patient who demonstrated a response to initial dose.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV infusion<i>:</i> Initial: Priming dose of 1 to 2 mg/kg repeated in 5 minutes. If no response, wait 1 to 2 hours and repeat priming dose. If some stimulation is noted, initiate infusion at 1 to 3 mg/minute (depending on size of patient/depth of CNS depression); suspend infusion if patient begins to awaken. Infusion should not be continued for &gt;2 hours. May reinstitute infusion as described above, including bolus, after rest interval of 30 minutes to 2 hours; maximum daily dose: 3,000 mg/<b>day</b>.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Respiratory depression following anesthesia:</b> Children &ge;12 years and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV: Initial: 0.5 to 1 mg/kg; may repeat at 5-minute intervals; maximum total dose: 2 mg/kg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Continuous IV infusion: Initial: 5 mg/minute until adequate response or adverse effects seen; decrease to 1 to 3 mg/minute; maximum total dose: 4 mg/kg (in an average adult, ~300 mg total dose)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Respiratory depression following anesthesia:</b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Intermittent injection: Initial: 0.5 to 1 mg/kg; may repeat at 5-minute intervals (only in patients who demonstrate initial response); maximum total dose: 2 mg/kg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV infusion: Initial: 5 mg/minute until adequate response or adverse effects seen; decrease to 1 to 3 mg/minute; maximum total dose: 4 mg/kg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Drug-induced CNS depression:</b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Intermittent injection: Initial: Priming dose of 1 to 2 mg/kg; repeat after 5 minutes; may repeat at 1 to 2 hour intervals (until sustained consciousness); maximum: 3,000 mg daily. May repeat in 24 hours if necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV infusion: Initial: Priming dose of 1 to 2 mg/kg repeated in 5 minutes. If no response, wait 1 to 2 hours and repeat priming dose. If some stimulation is noted, initiate infusion at 1 to 3 mg/minute (depending on size of patient/depth of CNS depression); suspend infusion if patient begins to awaken. Infusion should not be continued for &gt;2 hours. May reinstitute infusion as described above, including bolus, after rest interval of 30 minutes to 2 hours; maximum: 3,000 mg daily.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Acute hypercapnia secondary to COPD:</b> IV infusion: Initial: Initiate infusion at 1 to 2 mg/minute (depending on size of patient/depth of CNS depression); may increase to maximum rate of 3 mg/minute; infusion should not be continued for &gt;2 hours. Monitor arterial blood gases prior to initiation of infusion and at 30-minute intervals during the infusion (to identify possible development of acidosis/CO<sub>2</sub> retention). Additional infusions are not recommended (per manufacturer).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> There are no dosage adjustments provided in manufacturer's labeling (has not been studied); however, use caution in severe impairment due to the potential for altered pharmacokinetics.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> There are no dosage adjustments provided in manufacturer's labeling (has not been studied); however, use caution in severe impairment due to the potential for altered pharmacokinetics.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F162814\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dopram: 20 mg/mL (20 mL) [contains benzyl alcohol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 20 mg/mL (20 mL [DSC])</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F162799\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1058204\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Parenteral: IV: Administer as an intermittent bolus over 15 to 30 minutes or as an IV infusion. Avoid rapid infusion. Avoid extravasation; irritating to tissues. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F162827\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store intact vials at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1058203\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Respiratory stimulant for respiratory depression secondary to anesthesia, mild to moderate drug-induced respiratory and CNS depression, and acute hypercapnia secondary to COPD (FDA approved in ages &ge;12 years and adults); has also been used to treat apnea of prematurity refractory to methylxanthine therapy</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F162864\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Doxapram may be confused with doxazosin, doxepin, DOXOrubicin </p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dopram&reg; may be confused with DOPamine</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">International issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Doxapram may be confused with Doxinate brand name for doxylamine and pyridoxine [Italy]</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F162861\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Cardiovascular: Cardiac arrhythmia, change in pulse, chest pain, chest tightness, flattened T wave on ECG, flushing, increased blood pressure, phlebitis, ventricular fibrillation, ventricular tachycardia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Central nervous system: Apprehension, clonus, disorientation, dizziness, hallucination, headache, hyperactivity, hyperreflexia, involuntary muscle movements, paresthesia, positive Babinski sign, seizure</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Dermatologic: Burning sensation of skin, diaphoresis, pruritus</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Endocrine &amp; metabolic: Albuminuria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gastrointestinal: Bowel urgency, diarrhea, hiccups, nausea, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Genitourinary: Urinary incontinence, urinary retention</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hematologic &amp; oncologic: Decreased hematocrit, decreased hemoglobin, hemolysis, decreased red blood cells</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Neuromuscular &amp; skeletal: Fasciculations, laryngospasm, muscle spasm</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Ophthalmic: Mydriasis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Renal: Increased blood urea nitrogen</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Respiratory: Bronchospasm, cough, dyspnea, hyperventilation, hypoventilation (rebound), tachypnea</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Miscellaneous: Fever</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Rare but important or life-threatening: Agitation (emergence), prolonged Q-T interval on ECG (premature neonates), second degree atrioventricular block (premature neonates)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F162819\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to doxapram or any component of the formulation; significant cardiovascular impairment (eg, uncompensated heart failure, severe coronary artery disease); severe hypertension (including severe hypertension associated with hyperthyroidism or pheochromocytoma); cerebral edema, cerebral vascular accident, epilepsy or other convulsive disorders, head injury; mechanical disorders of ventilation (eg, mechanical obstruction, muscle paresis, neuromuscular blockade, flail chest, pneumothorax, acute asthma, pulmonary fibrosis), pulmonary embolism (proven or suspected)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F162803\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular effects: May cause dysrhythmias; monitor for disturbances of cardiac rhythm. If sudden hypotension develops during use, discontinue. Increases in blood pressure are generally modest; use is contraindicated in patients with severe hypertension.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CNS stimulation: May cause severe CNS stimulation, including seizures; anticonvulsants (as well as oxygen and resuscitative equipment) should be available to manage potential excessive CNS stimulation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cerebrovascular disease: Use with caution in patients with cerebrovascular disease; lowered pCO<sub>2</sub> induced by hyperventilation produces cerebral vasoconstriction and decreased circulation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Respiratory disease: Do <b>not</b> use in patients on mechanical ventilation. Use with caution in treating pulmonary disease; a pressor effect on pulmonary circulation may result in a fall in arterial pO<sub>2</sub>. If sudden dyspnea develops during use, discontinue. Doxapram causes patients to increase the work of breathing; therefore, do not increase the rate of infusion in an attempt to lower the pCO<sub>2</sub> in severely-ill COPD patients.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; MAO inhibitors (MAOIs): Use caution with coadministration; additive pressor effect may occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Sympathomimetics: Use caution with coadministration; additive pressor effect may occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Volatile anesthetics: If patient has received anesthesia with a volatile agent known to sensitize the myocardium to catecholamines, avoid use of doxapram until anesthetic has been eliminated to decrease the risk of ventricular tachycardia or ventricular fibrillation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Benzyl alcohol and derivatives: Some dosage forms may contain benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension and cardiovascular collapse (AAP [&quot;Inactive&quot; 1997]; CDC, 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors, 2001); avoid or use dosage forms containing benzyl alcohol with caution in neonates. See manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Administration: Avoid extravasation; doxapram may cause thrombophlebitis or local skin irritation. Hemolysis may result from rapid infusion.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Adequate airway required prior to use; consider airway protection in case of vomiting. Resuscitative equipment (in addition to anticonvulsants and oxygen) should be readily available; doxapram alone may not be sufficient to stimulate spontaneous breathing or provide sufficient arousal. Doxapram is neither an antagonist to skeletal muscle relaxants nor an opioid antagonist. Use with caution in patients with hypermetabolic states (eg, hyperthyroidism, pheochromocytoma).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25856120\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Recommended doses of doxapram for treatment of neonatal apnea will deliver 5.4 to 27 mg/kg/day of benzyl alcohol; the use of doxapram should be reserved for neonates who are unresponsive to the treatment of apnea with therapeutic serum concentrations of theophylline or caffeine; monitor benzyl alcohol exposure, particularly with prolonged therapy or high doses.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Possible adverse effects on mental development (based on developmental scales and index scoring) have been reported in former premature neonates (Lando 2005, Sreenan 2001). A case-controlled trial of 80 children who weighed &lt;1,250 g at birth (mean GA: ~26.5 weeks, corrected age at assessment: 18 months) reported a significant correlation between isolated adverse mental development and total cumulative dose of doxapram (mean: 2,233 mg [cases] vs 615 mg [controls]) and duration of therapy (mean: 45.2 days [cases] vs 19.4 days [controls]) (Sreenan 2001). Another report of 88 former premature neonates (GA &lt;28 weeks) showed an association between doxapram therapy and lower developmental scores later in infancy and early childhood (age at assessment was 9 to 15 months corrected age) (Lando 2005).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use with caution in premature neonates and infants; hypertension (dose related), irritability, jitteriness, erratic limb movements, excessive crying, sleep disturbances, abdominal distention, vomiting, NEC, increased gastric residuals, bloody stools, hyperglycemia, glycosuria, premature eruption of teeth, and QT prolongation resulting in heart block have been reported. Seizures have been reported in premature neonates who have additional seizure risk factors including a history of seizures, perinatal asphyxia, intracerebral hemorrhage or recent aminophylline, theophylline, or caffeine exposure.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299230\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F162808\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=13252&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cannabinoid-Containing Products: May enhance the tachycardic effect of Sympathomimetics.<b> Exceptions: </b>Cannabidiol.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cocaine (Topical): May enhance the hypertensive effect of Sympathomimetics. Management: Consider alternatives to use of this combination when possible. Monitor closely for substantially increased blood pressure or heart rate and for any evidence of myocardial ischemia with concurrent use.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Doxofylline: Sympathomimetics may enhance the adverse/toxic effect of Doxofylline. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Guanethidine: May enhance the arrhythmogenic effect of Sympathomimetics. Guanethidine may enhance the hypertensive effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iobenguane I 123: Sympathomimetics may diminish the therapeutic effect of Iobenguane I 123. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Linezolid: May enhance the hypertensive effect of Sympathomimetics. Management: Reduce initial doses of sympathomimetic agents, and closely monitor for enhanced pressor response, in patients receiving linezolid.  Specific dose adjustment recommendations are not presently available.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Monoamine Oxidase Inhibitors: May enhance the hypertensive effect of Doxapram.<b> Exceptions: </b>Tedizolid.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tedizolid: May enhance the hypertensive effect of Sympathomimetics. Tedizolid may enhance the tachycardic effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F162810\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F162821\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have not been observed in animal reproduction studies.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1058199\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Pulse oximetry, blood pressure, heart rate, ECG, arterial blood gases, deep tendon reflexes; additional monitoring for apnea: Number, duration, and severity of apneic episodes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1058202\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:0em;display:inline\">Apnea of prematurity: Data suggest a therapeutic serum level of at least 1.5 mg/L; toxicity becomes frequent at serum levels &gt;4 to 5 mg/L (Barb&eacute; 1999; Barrington 1987)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F162802\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Stimulates respiration through action on peripheral carotid chemoreceptors; respiratory center in medulla is also directly stimulated as dosage is increased</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F162818\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: Respiratory stimulation: Single IV injection: 20 to 40 seconds</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Peak effect: Single IV injection: 1 to 2 minutes </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Duration: Single IV injection: 5 to 12 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>d</sub>: Neonates: 4 to 7.3 L/kg </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Extensive in the liver to active metabolite (keto-doxapram) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination, serum: </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Neonates, premature: 6.6 to 12 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Adults: Mean: 3.4 hours (range: 2.4 to 4.1 hours)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Clearance: Neonates, premature: 0.44 to 0.7 L/hour/kg  </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323120\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Dopram Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg/mL (20 mL): $55.39</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6038604\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Boda (CN);</li>\n      <li>Caropraml (IN);</li>\n      <li>Dopram (AT, AU, BE, CH, DE, DK, EG, FI, FR, GR, IE, JP, NL, SA, ZA);</li>\n      <li>Mopram (KR);</li>\n      <li>Tapram (KR)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/doxapram-pediatric-drug-information/abstract-text/11487763 /pubmed\" target=\"_blank\" id=\"11487763 \">11487763 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics Committee on Drugs. &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/doxapram-pediatric-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Barb&eacute; F, Hansen C, Badonnel Y, Legagneur H, Vert P, Boutroy MJ. Severe side effects and drug plasma concentrations in preterm infants treated with doxapram. <i>Ther Drug Monit</i>. 1999;21(5):547-552.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/doxapram-pediatric-drug-information/abstract-text/10519454/pubmed\" target=\"_blank\" id=\"10519454\">10519454</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Barrington KJ, Finer NN, Torok-Both G, et al, &ldquo;Dose-Response Relationship of Doxapram in the Therapy for Refractory Idiopathic Apnea of Prematurity,&rdquo; <i>Pediatrics</i>, 1987, 80(1):22-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/doxapram-pediatric-drug-information/abstract-text/3110729/pubmed\" target=\"_blank\" id=\"3110729\">3110729</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bhatt-Mehta V and Schumacher RE, &ldquo;Treatment of Apnea of Prematurity,&rdquo; <i>Paediatr Drugs</i>, 2003, 5(3):195-210.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/doxapram-pediatric-drug-information/abstract-text/12608884 /pubmed\" target=\"_blank\" id=\"12608884 \">12608884 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol - United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. Available at <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/doxapram-pediatric-drug-information/abstract-text/6810084 /pubmed\" target=\"_blank\" id=\"6810084 \">6810084 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dopram (doxapram) [prescribing information]. Eatontown, NJ: West-Ward Pharmaceuticals; November 2011.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lando A, Klamer A, Jonsbo F, Weiss J, Greisen G. Doxapram and developmental delay at 12 months in children born extremely preterm. <i>Acta Paediatr</i>. 2005;94(11):1680-1681.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/doxapram-pediatric-drug-information/abstract-text/16303710/pubmed\" target=\"_blank\" id=\"16303710\">16303710</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Maillard C, Boutroy MJ, Fresson J, et al, &ldquo;QT Interval Lengthening in Premature Infants Treated With Doxapram,&rdquo; <i>Clin Pharmacol Ther</i>, 2001, 70(6):540-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/doxapram-pediatric-drug-information/abstract-text/11753270/pubmed\" target=\"_blank\" id=\"11753270\">11753270</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Peliowski A, Finer NN. A blinded, randomized, placebo-controlled trial to compare theophylline and doxapram for the treatment of apnea of prematurity. <i>J Pediatr</i>. 1990;116(4):648-653.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/doxapram-pediatric-drug-information/abstract-text/2181103/pubmed\" target=\"_blank\" id=\"2181103\">2181103</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sreenan C, Etches PC, Demianczuk N, Robertson CM. Isolated mental developmental delay in very low birth weight infants: association with prolonged doxapram therapy for apnea. <i>J Pediatr</i>. 2001;139(6):832-837.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/doxapram-pediatric-drug-information/abstract-text/11743509/pubmed\" target=\"_blank\" id=\"11743509\">11743509</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tay-Uyboco J, Kwiatkowski K, Cates DB, Seifert B, Hasan SU, Rigatto H. Clinical and physiological responses to prolonged nasogastric administration of doxapram forapnea of prematurity. <i>Biol Neonate</i>. 1991;59(4):190-200.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/doxapram-pediatric-drug-information/abstract-text/2070020/pubmed\" target=\"_blank\" id=\"2070020\">2070020</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 13252 Version 100.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F162830\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1058200\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F11442336\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F47068082\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F162814\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F162799\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1058204\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F162827\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1058203\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F162864\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F162861\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F162819\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F162803\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F25856120\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299230\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F162808\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F162810\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F162821\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1058199\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F1058202\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F162802\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F162818\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323120\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F6038604\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/13252|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=doxapram-drug-information\" class=\"drug drug_general\">Doxapram: Drug information</a></li></ul></div></div>","javascript":null}